SCHEMBL211587

SCHEMBL211587

COC(=O)c1ccc(CNc2nc(-c3cccnc3)cs2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.69
MAPT P10636 5/20 0.58
SMN1; SMN2 Q16637 5/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
HPGD P15428 1/20 0.55
HSD17B10 Q99714 1/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
LMNA P02545 1/20 0.54
TDP1 Q9NUW8 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
KDM4E B2RXH2 2/20 0.53
RECQL P46063 1/20 0.53
ESR2 Q92731 1/20 0.53
NPY5R Q15761 1/20 0.53
HTT P42858 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16211539 0.89 HDAC3 (0.64) ALDH1A1MAPTSMN1; SMN2HPGDNPC1
SCHEMBL211074 0.88 ALDH1A1 (0.78) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL716830 0.84 ABL1 (0.60) ALDH1A1NPC1RAB9ATDP1HDAC3
SCHEMBL206769 0.83 ALDH1A1 (0.90) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL16211806 0.82 MEN1 (0.56) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
Bromide SCHEMBL7215296 0.81 CYP19A1 (0.67) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL205918 0.80 ALDH1A1 (0.69) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL212154 0.80 HDAC1 (0.64) ALDH1A1SMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL1065202 0.80 HDAC3 (0.74) CYP3A4HDAC3HDAC1HDAC2HDAC8
SCHEMBL204418 0.80 ALDH1A1 (0.72) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 ALDH1A1 680/4885MAPT 3612/4885SMN1; SMN2 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.